MENU
+Compare
CTMX
Stock ticker: NASDAQ
AS OF
Apr 29, 04:59 PM (EDT)
Price
$0.66
Change
-$0.05 (-7.04%)
Capitalization
56.7M

CTMX CytomX Therapeutics Forecast, Technical & Fundamental Analysis

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment... Show more

Industry: #Biotechnology
CTMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CTMX with price predictions
Apr 28, 2025

Momentum Indicator for CTMX turns positive, indicating new upward trend

CTMX saw its Momentum Indicator move above the 0 level on April 15, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for CTMX just turned positive on April 14, 2025. Looking at past instances where CTMX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

CTMX moved above its 50-day moving average on April 17, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CTMX crossed bullishly above the 50-day moving average on April 24, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CTMX advanced for three days, in of 253 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CTMX moved out of overbought territory on April 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTMX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CTMX broke above its upper Bollinger Band on April 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CTMX entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (14.339). P/E Ratio (1.715) is within average values for comparable stocks, (64.948). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.831). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (0.400) is also within normal values, averaging (255.967).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CTMX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
CTMX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CTMX is expected to report earnings to fall 71.59% to 6 cents per share on May 07

CytomX Therapeutics CTMX Stock Earnings Reports
Q1'25
Est.
$0.06
Q4'24
Beat
by $0.43
Q3'24
Beat
by $0.24
Q2'24
Beat
by $0.02
Q1'24
Beat
by $0.25
The last earnings report on March 06 showed earnings per share of 21 cents, beating the estimate of -20 cents. With 1.97M shares outstanding, the current market capitalization sits at 56.70M.
A.I. Advisor
published General Information

General Information

an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
151 Oyster Point Boulevard
Phone
+1 650 515-3185
Employees
122
Web
https://www.cytomx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RYAN65.380.53
+0.82%
Ryan Specialty Holdings
BANR61.630.11
+0.18%
Banner Corp
AUDC9.470.01
+0.11%
AudioCodes Ltd
CI334.82-0.54
-0.16%
Cigna Group (The)
DTIL5.11-0.22
-4.13%
Precision BioSciences

CTMX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CTMX has been loosely correlated with MLEC. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if CTMX jumps, then MLEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CTMX
1D Price
Change %
CTMX100%
-0.30%
MLEC - CTMX
42%
Loosely correlated
+5.23%
PYXS - CTMX
39%
Loosely correlated
-1.89%
BCAB - CTMX
39%
Loosely correlated
+0.98%
XNCR - CTMX
38%
Loosely correlated
+0.86%
TECH - CTMX
38%
Loosely correlated
+0.02%
More